Fundamentals-based quality & risk · not a recommendation
Arvee Laboratories (India) Ltd. scores 40/100 (Caution) on the Orion Score — weak business quality (39), poor growth (20), strong balance-sheet safety (79) and rich valuation (17). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
82/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q3 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q3 2026 | ₹9.78 | ₹1.83 | 13.5% | ₹1.66 |
| Q2 2026 | ₹3.45 | ₹0.01 | -5.2% | ₹0.01 |
| Q1 2026 | ₹7.48 | ₹0.17 | 0.7% | ₹0.15 |
| Q4 2025 | ₹6.4 | ₹0.07 | -0.6% | — |
| Q3 2025 | ₹8.91 | ₹0.15 | 0.8% | ₹0.14 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹38.44 | ₹2.15 | ₹4.17 | 6.4% |
| FY 2024 | ₹30.34 | ₹1.05 | ₹3.52 | 4.9% |
| FY 2023 | ₹61.28 | ₹4.12 | ₹8.53 | 8.6% |
| FY 2022 | ₹39.69 | ₹2.57 | ₹6.15 | 7.6% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| ARVEE ★ | ₹169 Cr | 81.73 | 7.30% | 7.77% | 0.03x | 13.51% |
| AETHER | ₹18,945 Cr | 86.46 | 11.68% | 9.38% | 0.19x | 21.06% |
| ATUL | ₹18,865 Cr | 27.80 | 10.56% | 11.53% | 0.03x | 17.07% |
| CHAMBLFERT | ₹17,268 Cr | 8.84 | 19.66% | 20.45% | 0.10x | 5.92% |
| ANURAS | ₹14,226 Cr | 81.35 | 8.65% | 5.76% | 0.41x | 18.15% |
| ACI | ₹6,850 Cr | 64.29 | 6.58% | 5.55% | 0.24x | 6.94% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹37.57 | ₹38.56 | ₹38.69 | ₹38.68 |
| Equity | ₹31.26 | ₹29.11 | ₹28.06 | ₹23.94 |
| Total Debt | ₹1.03 | ₹1 | ₹1 | ₹3.13 |
| Cash | ₹0.21 | ₹1.85 | ₹0.54 | ₹1.28 |
| Net Debt | ₹0.82 | — | ₹0.46 | ₹1.85 |
| Working Capital | ₹15.84 | ₹9.85 | ₹12.73 | ₹8.87 |
Q3 FY2026
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q3 FY2026 | 73.5% | — | — | 26.5% |
| Q2 FY2026 | 73.5% | — | — | 26.5% |
| Q1 FY2026 | 73.5% | — | — | 26.5% |
| Q4 FY2025 | 73.5% | — | — | 26.5% |
| Q3 FY2025 | 73.5% | — | — | 26.5% |
| Q2 FY2025 | 73.5% | — | — | 26.5% |
| Q1 FY2025 | 73.5% | — | — | 26.5% |
| Q4 FY2024 | 73.5% | — | — | 26.5% |
No recent corporate actions
Ask: "Is Arvee Laboratories (India) Ltd. stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Arvee Laboratories (India) Ltd. is listed on the NSE under the Chemicals sector, Specialty Chemicals industry. ISIN: INE006Z01016. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.